The role of interleukin 18 in the pathogenesis of hypertension-induced vascular disease

Nature Clinical Practice Cardiovascular Medicine

Volumn 6, Issue 3, 2009, Pages 192-199

  Rabkin, Simon W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA 2 ADRENERGIC RECEPTOR; COLLAGENASE 3; ENDOTHELIN RECEPTOR ANTAGONIST; FAS ANTIGEN; FAS LIGAND; GELATINASE A; GELATINASE B; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 18; INTERLEUKIN 18 RECEPTOR; INTERLEUKIN 18 RECEPTOR ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MINERALOCORTICOID ANTAGONIST; MITOGEN ACTIVATED PROTEIN KINASE P38; NORADRENALIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR; UNINDEXED DRUG;

AGE; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CELL MIGRATION; CELL PROLIFERATION; CORONARY ARTERY DISEASE; DRUG MECHANISM; ENDOTHELIUM CELL; ESSENTIAL HYPERTENSION; HUMAN; HYPERTENSION; INFLAMMATION; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; VASCULAR DISEASE;

ANGIOTENSINS; CATECHOLAMINES; HUMANS; HYPERTENSION; INTERLEUKIN-18; MATRIX METALLOPROTEINASES; OXIDATIVE STRESS; PERIPHERAL VASCULAR DISEASES;

EID: 61449215204     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio1453     Document Type: Review

References (70)

1. Edwards KM et al. (2007) The potential antiinflammatory benefits of improving physical fitness in hypertension. J Hypertens 25 1533-1542
2. Vaziri ND and Rodríguez-Iturbe B (2006) Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nat Clin Pract Nephrol 2: 582-593
3. Streja D et al. (2003) Associations between inflammatory markers, traditional risk factors, and complications in patients with type 2 diabetes mellitus. J Diabetes Complications 17: 120-127
4. Jenny NS et al. (2007) Inflammation biomarkers and near-term death in older men. Am J Epidemiol 165: 684-695
5. Ghayur T et al. (1997) Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature 386: 619-623
6. Akita K et al. (1997) Involvement of caspase-1 and caspase-3 in the production and processing of mature human interleukin 18 in monocytic THP.1 cells. J Biol Chem 272: 26595-26603
7. Torigoe K et al. (1997) Purification and characterization of the human interleukin-18 receptor. J Biol Chem 272: 25737-25742
8. Kato Z et al. (2003) The structure and binding mode of interleukin-18. Nat Struct Biol 10: 966-971
9. Nakanishi K et al. (2001) Interleukin-18 regulates both Th1 and Th2 responses. Ann Rev Immunol 19: 423-474
10. Gracie JA et al. (2003) Interleukin-18. J Leukoc Biol 73 213-224
11. Gerdes N et al. (2002) Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: Implications for atherogenesis. J Exp Med 195: 245-257
12. Packard RR and Libby P (2008) Inflammation in atherosclerosis: From vascular biology to biomarker discovery and risk prediction. Clin Chem 54: 24-38
13. Thompson SR and Humphries SE (2007) Interleukin-18 genetics and inflammatory disease susceptibility. Genes Immun 8: 91-99
14. Chandrasekar B et al. (2006) Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. J Biol Chem 281: 15099-15109
15. Li SL et al. (2006) Enhanced proatherogenic responses in macrophages and vascular smooth muscle cells derived from diabetic db/db mice. Diabetes 55: 2611-2619
16. Tiret L et al. (2005) Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation 112: 643-650
17. Blankenberg S et al. (2006) Haplotypes of the caspase-1 gene, plasma caspase-1 levels, and cardiovascular risk. Circ Res 99 102-108
18. Hulthe J. et al. (2006) Plasma interleukin (IL)-18 concentrations is elevated in patients with previous myocardial infarction and related to severity of coronary atherosclerosis independently of C-reactive protein and IL-6. Atherosclerosis 188: 450-454
19. Chapman CM et al. (2006) Interleukin-18 levels are not associated with subclinical carotid atherosclerosis in a community population. The Perth Carotid Ultrasound Disease Assessment Study (CUDAS). Atherosclerosis 189: 414-419
20. Vilarrasa N et al. (2006) IL-18: Relationship with anthropometry, body composition parameters, leptin and arterial hypertension. Horm Metab Res 38: 507-512
21. Yamagami H et al. (2005) Associations of serum IL-18 levels with carotid intima-media thickness. Arterioscler Thromb Vasc Biol 25: 1458-1462
22. Blankenberg S et al. (2003) Interleukin-18 and the risk of coronary heart disease in European men: The Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 108: 2453-2459
23. Evans J et al. (2007) The association of interleukin-18 genotype and serum levels with metabolic risk factors for cardiovascular disease. Eur J Endocrinol 157: 633-640
24. Hung J et al. (2008) C-reactive protein and interleukin-18 levels in relation to coronary heart disease: Prospective cohort study from Busselton Western Australia. Heart Lung Circ 17: 90-95
25. Thorand B et al. (2005) Elevated levels of interleukin-18 predict the development of type 2 diabetes: Results from the MONICA/KORA Augsburg Study, 1984-2002. Diabetes 54: 2932-2938
26. Hung J et al. (2005) Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler Thromb Vasc Biol 25: 1268-1273
27. Zirlik A et al. (2007) Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis: Results from the Dallas Heart Study. Arterioscler Thrombosis Vasc Biol 27: 2043-2049
28. Tso TK et al. (2006) Relationship of plasma interleukin-18 concentrations to traditional and non-traditional cardiovascular risk factors in patients with systemic lupus erythematosus. Rheumatology (Oxford) 45: 1148-1153
29. Rabkin SW (2007) Epicardial fat: Properties, function and relationship to obesity. Obes Rev 8: 253-261
30. Rabkin SW et al. (1977) Relation of body weight to development of ischemic heart disease in a cohort of young North American men after a 26 year observation period: The Manitoba Study. Am J Cardiol 39 452-458
31. Nevill AM et al. (2006) Relationship between adiposity and body size reveals limitations of BMI. Am J Phys Anthropol 129: 151-156
32. Cuspidi C et al. (2002) Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: The Assessment of Prognostic Risk Observational Survey. J Hypertens 20: 1307-1314
33. Lorenz MW et al. (2007) Prediction of clinical cardiovascular events with carotid intima-media thickness: A systematic review and meta-analysis. Circulation 115: 459-467
34. Korshunov VA et al. (2006) Interleukin-18 and macrophage migration inhibitory factor are associated with increased carotid intima-media thickening. Arterioscler, Thromb Vasc Biol 26: 295-300
35. Aso Y et al. (2003) Relationships of plasma interleukin-18 concentrations to hyperhomocysteinemia and carotid intimal-media wall thickness in patients with type 2 diabetes. Diabetes Care 26 2622-2627
36. Bis JC et al. (2008) Variation in inflammation-related genes and risk of incident nonfatal myocardial infarction or ischemic stroke. Atherosclerosis 198: 166-173
37. Chandrasekar B et al. (2004) Activation of intrinsic and extrinsic proapoptotic signaling pathways in interleukin-18-mediated human cardiac endothelial cell death. J Biol Chem 279: 20221-20233
38. Chandrasekar B et al. (2006) Interleukin-18 induces human cardiac endothelial cell death via a novel signaling pathway involving NF-kappaB-dependent PTEN activation. Biochem Biophys Res Commun 339: 956-963
39. Sahar S et al. (2005) Angiotensin II enhances interleukin-18 mediated inflammatory gene expression in vascular smooth muscle cells: A novel cross-talk in the pathogenesis of atherosclerosis. Circ Res 96: 1064-1071
40. Chandrasekar B et al. (2005) The pro-atherogenic cytokine interleukin-18 induces CXCL16 expression in rat aortic smooth muscle cells via MyD88, interleukin-1 receptor-associated kinase, tumor necrosis factor receptor-associated factor 6, c-Src, phosphatidylinositol 3-kinase, Akt, c-Jun N-terminal kinase, and activator protein-1 signaling. J Biol Chem 280: 26263-26277
41. Yang H et al. (1989) Autoradiographic study of smooth muscle cell proliferation in spontaneously hypertensive rats. Clin Sci (Lond) 76: 475-478
42. Izzard AS et al. (2005) Small artery structure and hypertension: adaptive changes and target organ damage. J Hypertens 23: 247-250
43. Schwartz SM et al. (1986) Replication of smooth muscle cells in vascular disease. Circ Res 58: 427-444
44. Paravicini TM and Touyz RM (2006) Redox signaling in hypertension. Cardiovasc Res 71: 247-258
45. Williams HC and Griendling KK (2007) NADPH oxidase inhibitors: New antihypertensive agents? J Cardiovasc Pharmacol 50: 9-16
46. Clempus RE and Griendling KK (2006) Reactive oxygen species signaling in vascular smooth muscle cells. Cardiovasc Res 71: 216-225
47. Elbim C et al. (2005) Interleukin-18 primes the oxidative burst of neutrophils in response to formyl-peptides: Role of cytochrome b558 translocation and N-formyl peptide receptor endocytosis. Clin Diagn Lab Immunol 12: 436-446
48. Wyman TH et al. (2002) Physiological levels of interleukin-18 stimulate multiple neutrophil functions through p38 MAP kinase activation. J Leukoc Biol 72: 401-409
49. Escobales N and Crespo MJ (2005) Oxidative-nitrosative stress in hypertension. Curr Vasc Pharmacol 3: 231-246
50. Doi T et al. (2008) Aldosterone induces interleukin-18 through endothelin-1, angiotensin II, Rho/Rho-kinase, and PPARs in cardiomyocytes. Am J Physiol Heart Circ Physiol 295: H1279-H1287
51. Brown MJ and Macquin I (1981) Is adrenaline the cause of essential hypertension? Lancet 2: 1079-1082
52. de Champlain J et al. (1989) The sympatho-adrenal tone and reactivity in human hypertension. Clin Exp Hypertens A 11(suppl 1): 159-171
53. Rumantir MS et al. (2000) The 'adrenaline hypothesis' of hypertension revisited: Evidence for adrenaline release from the heart of patients with essential hypertension. J Hypertens 18: 717-723
54. Chandrasekar B et al. (2004) Beta-adrenergic stimulation induces interleukin-18 expression via beta2-AR, PI3K, Akt, IKK, and NF-kappaB. Biochem Biophys Res Commun 319: 304-311
55. Ra HJ and Parks WC (2007) Control of matrix metalloproteinase catalytic activity. Matrix Biol 26: 587-596
56. Visse R and Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ Res 92: 827-839
57. Galis ZS and Khatri JJ (2002) Matrix metalloproteinases in vascular remodeling and atherogenesis: The good, the bad, and the ugly. Circ Res 90: 251-262
58. Yasmin et al. (2005) Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 25: 372-378
59. Derosa G et al. (2006) Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium 13: 227-231
60. Tayebjee MH et al. (2005) Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases-1 and -2 levels in gestational hypertension. Am J Hypertens 18: 325-329
61. Zervoudaki A et al. (2003) Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment. J Hum Hypertens 17: 119-124
62. Li-Saw-Hee FL et al. (2000) Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy. Int J Cardiol 75: 43-47
63. Ergul A et al. (2004) Downregulation of vascular matrix metalloproteinase inducer and activator proteins in hypertensive patients. Am J Hypertens 17: 775-782
64. Zhou S et al. (2007) Matrix metalloproteinase-9 polymorphism contributes to blood pressure and arterial stiffness in essential hypertension. J Hum Hypertens 21: 861-867
65. Tayebjee MH et al. (2004) Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 in type 2 diabetes: Effect of 1 year's cardiovascular risk reduction therapy. Diabetes Care 27 2049-2051
66. Chew DK et al. (2004) Matrix metalloproteinase-specific inhibition of Ca2+ entry mechanisms of vascular contraction. J Vasc Surg 40: 1001-1010
67. Novak A and Dedhar S (1999) Signaling through beta-catenin and Lef/Tcf. Cell Mol Life Sci 56: 523-537
68. Johnson C and Galis ZS (2004) Matrix metalloproteinase-2 and -9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler Thromb Vasc Biol 24: 54-60
69. Sinha I et al. (2006) The nitric oxide donor DETA-NONOate decreases matrix metalloproteinase-9 expression and activity in rat aortic smooth muscle and abdominal aortic explants. Ann Vasc Surg 20: 92-98
70. Minoguchi K et al. (2005) Increased carotid intima-media thickness and serum inflammatory markers in obstructive sleep apnea. Am J Respir Crit Care Med 172: 625-630